Gilead has signed a three-year deal with Google’s life science division Verily to work on identifying the immunological and molecular drivers behind three inflammatory diseases.
Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious alliance to develop new cancer therapies.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
